Currently there is no curative treatment available for patients with peritoneal mesothelioma (‘asbest cancer’); after surgical removal, the tumor eventually recurs. Teaching the patient’s own immune system to kill tumor cells could help in preventing recurrance.
Vaccination based on immune-stimulating dendritic cells is safe, with only minimal (flu-like) side effects, and initial studies in lung mesothelioma patients are promising. In MESOPEC, we will study the added-value of such vaccination in preventing recurrence of surgically-resected peritoneal mesothelioma.
Dendritic cells derived from the patient’s own white blood cells will be loaded with proteins from a mesothelioma cell line, and the patients will receive in total 5 vaccinations using these loaded cells.